SELLAS Life Sciences’ cancer vaccine galinpepimut-S (GPS) met the primary overall survival endpoint in the Phase 3 REGAL trial, reducing the risk of death by 41% and extending median survival from 14.7 months in the control group to 24.0 months. The trial’s risk ratio was 0.59, with a two-sided p-value of 0.035. The analysis was conducted after the prespecified 80 events, with no new safety signals. The company plans to discuss an accelerated regulatory submission pathway with the FDA and intends to submit a Biologics License Application in the first half of 2027.
Source:Blockonomi · Read original
Leave a Reply